Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01741142 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of ABT-436 in Major Depressive Disorder
A Phase 2 study, sponsored by AbbVie (prior sponsor, Abbott).
- Terminated
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT01741142 is a Phase 2 study that was terminated before completion, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 19 participants.
The verdict
NCT01741142, a Phase 2 study, was terminated before completion, sponsored by AbbVie (prior sponsor, Abbott).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose is to study the efficacy and safety of ABT-436 in Major Depressive Disorder.
Interventions
- DRUG Placebo
- DRUG Escitalopram
- DRUG ABT-436
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2012-01 |
| Est. Completion | 2015-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01741142
The ClinicalTrials.gov registry entry for NCT01741142 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01741142 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01741142 about?
NCT01741142 is a clinical study titled "Efficacy and Safety Study of ABT-436 in Major Depressive Disorder". The purpose is to study the efficacy and safety of ABT-436 in Major Depressive Disorder.
What is the current status of trial NCT01741142?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2012-01. Estimated completion is 2015-08.
What interventions are being tested in trial NCT01741142?
The interventions under investigation include: Placebo (DRUG), Escitalopram (DRUG), ABT-436 (DRUG).
Who is sponsoring clinical trial NCT01741142?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.